Navigation Links
Novelos Therapeutics and MUSC Present Two Posters at AACR 2007,Annual Meeting

NEWTON, Mass.--(BUSINESS WIRE)--Apr 16, 2007 - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the company, in collaboration with Dr. Kenneth Tew and Dr. Danyelle Townsend of the Medical University of South Carolina (MUSC), is making two poster presentations at the ongoing American Association for Cancer Research annual meeting. These presentations will highlight in vivo and in vitro findings with NOV-002, which is currently in a pivotal Phase 3 trial for non-small cell lung cancer and Phase 2 trials for other oncology indications. The posters are available at www.novelos.com 'Our Products', 'NOV-002' section.

"As clinical development of NOV-002 progresses, we continue to add to our understanding of its molecular and cellular mechanisms of action as they may relate to therapeutic activity," said Christopher Pazoles, Ph.D., Vice President of Research & Development of Novelos. "Our ongoing and broad-ranging research collaboration with Drs. Tew and Townsend at MUSC is an important part of that effort."

About Novelos Therapeutics, Inc.

Novelos Therapeutics, Inc. is a biopharmaceutical company commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. NOV-002, the lead compound currently in Phase 3 development for lung cancer under a SPA and Fast Track, acts together with chemotherapy as a chemoprotectant and an immunomodulator. NOV-002 is also in Phase 2 development for chemotherapy-resistant ovarian cancer and early-stage breast cancer, and is in addition being developed for acute radiation injury. NOV-205 acts as a hepatoprotective agent with immunomodulating and anti-inflammatory properties. NOV-205 is in Phase 1b development for chronic hepatitis C non-responders. Both compounds have completed clinical trials in humans and have been approved
'"/>




Page: 1 2

Related medicine technology :

1. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:5/5/2015)... May 5, 2015  Vaccinogen, Inc. (OTC.QB: VGEN), a ... of Directors has unanimously elected Co-founder, President, Chief Executive ... to the role of Chairman of the Board. Mr. ... who resigned from the Board and his role as ... role to pursue his candidacy for the President of ...
(Date:5/5/2015)... Bio-Techne Corporation (NASDAQ: TECH ) announced ... a dividend of $0.32 per share for the quarter ... payable May 29, 2015 to all common shareholders of ... be considered by the Board of Directors on a ... ) is a global life sciences company providing innovative ...
(Date:5/5/2015)... , May 05, 2015 Research and Markets ... of the "Will Theranos Turn the Lab Industry ... Theranos has received much praise along with a healthy ... "gone public" with their potentially disruptive laboratory solution. Behind ... Has Theranos scaled microfluidic technology across a ...
Breaking Medicine Technology:Vaccinogen Names Co-Founder and CEO Andrew L. Tussing as Chairman of the Board 2Vaccinogen Names Co-Founder and CEO Andrew L. Tussing as Chairman of the Board 3Will Theranos Turn the Lab Industry Upside Down? 2
... Mass. , June 1 SynapDx Corp., a new company ... autism, announced the completion of a $9 million Series A ... Partners. , , , ... profound effect on children and their families," said Stanley N. Lapidus ...
... FRANCISCO , June 1 Prostate cancer ... FIRMAGON® (degarelix for injection) after one year of treatment ... of a Phase III extension study(1) presented here at ... used in monitoring prostate cancer patients, treatment response, and ...
Cached Medicine Technology:Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year 2Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year 3Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year 4Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year 5
(Date:5/5/2015)... 2015 In the upbeat Moms Helping Moms ... moms to support each other. Parenting is a tough ... makes it so much easier. Mothers talk about how ... less alone and help them realize there’s no perfect parent; ... who are clearly dear friends share that it's just that, ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Specialty ... collaborating with American Eagle Outfitters on a collection ... natural beauty. , For the debut five-piece ... Aerie by American Eagle ; the retailer's ... body-image campaign, called "Aerie REAL," uses models of ...
(Date:5/5/2015)... 05, 2015 Igantia , an ... leads an international initiative to examine key biological milestones ... human lifespan. Scientists at Igantia believe that better ... the initiation of her menstrual cycle to her transition ... aging and, ultimately, extend the lifespan. , By ...
(Date:5/5/2015)... 05, 2015 Care Logistics ... called “Medicare Breakeven Challenges? A Model to ... ,     Formulas for two critical ... but should be ,     A model ... space” and ensures sustained efficient operations , ...
(Date:5/5/2015)... 05, 2015 Every year, news articles appear ... out, the worst dry eye season is spring, also known ... most of the United States. The only season offering a ... Sharon Kleyne, host of the Sharon Kleyne Hour™ Power of ... radio show of May 11, 2015. Kleyne is the inventor ...
Breaking Medicine News(10 mins):Health News:Just In Time For Mother’s Day, Healthy Birth Day Releases Video Titled “Moms Helping Moms” Encouraging Mothers To Band Together 2Health News:BLKBOXLabs Finds Real Beauty in Beauty For Real and American Eagle Outfitters’ Aerie-Branded Beauty Line 2Health News:BLKBOXLabs Finds Real Beauty in Beauty For Real and American Eagle Outfitters’ Aerie-Branded Beauty Line 3Health News:Igantia Announces Digital Initiative to Decode Longevity 2Health News:Care Logistics Publishes a New Hospital Guidebook for Achieving Medicare Breakeven 2Health News:Nature’s Tears EyeMist tear film supplement soothes dry eye caused by spring pollen season, reports inventor Sharon Kleyne 2Health News:Nature’s Tears EyeMist tear film supplement soothes dry eye caused by spring pollen season, reports inventor Sharon Kleyne 3
... Unfortunately for us, there is no formula for fulfillment or ... religion and science time and again for answers to our ... Confucius and Plato, and science continues to piece together some ... Psychologists Nansook Park and Christopher Peterson from the University ...
... at Massachusetts General Hospital (MGH) has been awarded $15 ... Diseases to investigate how the hepatitis C virus (HCV) ... The five-year grant will support a Cooperative Center for ... on how some individuals successfully recover from HCV while ...
... network of medical research institutions across the United States ... to gather critical data about influenza vaccines, including two ... the direction of the National Institute of Allergy and ... Health. "With the emergence of the 2009 ...
... ROSEMONT, Ill., July 22 The American Academy of Orthopaedic ... the treatment of pediatric diaphyseal femur fractures . ... (the bone in the thigh) is a very common childhood injury. ... treatment options for femur fracture, a thighbone injury occurring in an ...
... , WASHINGTON, July 22 ... Medical Doctors Alfred Bonati, M.D., participated yesterday in ... Committee Chairman Michael Steele. Dr. Bonati and other attendees from ... impact of health-care reform on physicians, small businesses, employees and ...
... PHILADELPHIA, July 22 New research from The Children,s ... in acting as gatekeepers for infectious viruses. By using mice genetically ... the study team prevented infection by a common virus that causes ... "This finding is a step to understanding how cell receptors ...
Cached Medicine News:Health News:Life lessons: Where psychology stands on living well 2Health News:Mass. General-based research center will investigate why immune system fails to control hepatitis C 2Health News:NIAID set to launch clinical trials to test 2009 H1N1 influenza vaccine candidates 2Health News:NIAID set to launch clinical trials to test 2009 H1N1 influenza vaccine candidates 3Health News:American Academy of Orthopaedic Surgeons Approves New Guideline for the Treatment of Pediatric Diaphyseal Femur Fractures 2Health News:American Academy of Orthopaedic Surgeons Approves New Guideline for the Treatment of Pediatric Diaphyseal Femur Fractures 3Health News:American Academy of Orthopaedic Surgeons Approves New Guideline for the Treatment of Pediatric Diaphyseal Femur Fractures 4Health News:Internationally Renowned Surgeon Reaches out to RNC, Hispanic Community 2Health News:Eliminating Cell Receptor Prevents Infections in Animal Study 2Health News:Eliminating Cell Receptor Prevents Infections in Animal Study 3
Narrow smooth jaws. Serrated handle with polished finish....
1 mm smooth 45 degrees angled jaws. Cross action serrated handle with polished finish....
Round solid 15 mm wide lower plate. Open upper plate with inside diameter 12 mm. Serrated handle with locking thumb screw and polished finish....
Oval solid 17 mm wide lower plate. Open upper plate with inside dimensions 12 mm x 14 mm. Serrated handle with locking thumb screw and polished finish. Most popular size or model....
Medicine Products: